Juan Carlos Rico Crescencio

Role not yet determined Is this you? Add your title

UAMS

Also affiliated: Lincoln Medical Center (2012); Northwell Health (2014); University of Arkansas Medical Center (2025)

6 h-index 26 pubs 140 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group

OverviewAI-generated summary

Juan Carlos Rico Crescencio's research focuses on the spectrum of infections and treatment outcomes in immunocompromised patients, particularly those with hematological malignancies. His work has investigated the infectious complications associated with novel therapies, such as bispecific antibody treatments for relapsed refractory multiple myeloma. He has also examined risk factors for hospital admission following specific treatments, like SARS-CoV-2 monoclonal antibody therapy.

Dr. Crescencio's publications include case reports detailing rare infections in patients with conditions like diffuse large B-cell lymphoma and multiple myeloma, including Chryseobacterium gleum pneumonia and disseminated Bartonella henselae infection. He has also explored the use of electronic medical record alerts for clinical interventions, such as vancomycin time outs, and the implementation of mobile phone interventions to improve outcomes in patients with HIV. His scholarship metrics include an h-index of 6 across 26 publications, with 129 total citations.

Metrics

h-index: 6
Publications: 26
Citations: 140

Selected Publications

Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell Transplantation (2025)

Cureus DOI OpenAlex
A case of primary intraocular B-cell lymphoma masquerading alongside varicella-zoster virus retinitis (2025)

American Journal of Ophthalmology Case Reports DOI OpenAlex
P-842. Community-onset vs. Hospital-onset Staphylococcus aureus Bacteremia: Implications for Patients and Healthcare Systems (2025)

Open Forum Infectious Diseases DOI OpenAlex
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma (2023)

Haematologica 58 citations DOI OpenAlex
1791. Leveraging EMR Alerts for Vancomycin Time Outs (2022)

Open Forum Infectious Diseases DOI OpenAlex
1273. Implementation of a Mobile Phone Intervention Method to Improve Clinical Outcomes in Patients with HIV (2022)

Open Forum Infectious Diseases DOI OpenAlex
1790. Dethroning Vancomycin: A Multifaceted Stewardship Approach to Reduce Vancomycin in an Academic Medical Center (2022)

Open Forum Infectious Diseases DOI OpenAlex
Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant (2022)

Blood DOI OpenAlex
Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Constrained State (2022)

Laboratory Medicine 1 citation DOI OpenAlex
17. A Retrospective Cohort Study of Influenza Infected Multiple Myeloma Patients Comparing Clinical Outcomes Between Vaccinated and Unvaccinated (2021)

Open Forum Infectious Diseases DOI OpenAlex
519. Risk Factor Analysis for Hospital Admission Following Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Monoclonal Antibody Treatment (2021)

Open Forum Infectious Diseases 4 citations DOI OpenAlex
1327. Human Rhinovirus Infection in Multiple Myeloma Patients: Effect on Morbidity and Mortality (2021)

Open Forum Infectious Diseases DOI OpenAlex
Chryseobacterium gleum Causing Healthcare-Associated Pneumonia in an Adult Male With Diffuse Large B Cell Lymphoma (2021)

Cureus 5 citations DOI OpenAlex
46. Antimicrobial Stewardship’s Selective Antibiotic Suppression Does Not Lead to Adverse Outcomes in Neutropenic Patients with Gram-Negative Bacteremia (2020)

Open Forum Infectious Diseases DOI OpenAlex
Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes (2019)

Transplant Infectious Disease 9 citations DOI OpenAlex